ArticleBMC pharmacology & toxicology2025
Hepatoprotective effect of geraniol against chlorpyrifos ethyl-induced liver injury: an experimental animal study.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the possible hepatotoxic effect of chlorpyrifos ethyl, which may pose a potential danger to the environment and human health, on liver, oxidant and antioxidant parameters and the hepatoprotective role of geraniol against this effect.
methodsThirty-two Wistar albino male rats were included in the study. The study continued for 28 days. Rats were divided into four equal groups: Control, chlorpyrifos ethyl (CE), geraniol and CE + geraniol. CE was applied to induce liver injury, while geraniol was administered by oral gavage. To assess liver injury, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) levels were analyzed from blood serum samples. In addition, liver injury was assessed at the tissue level by analyzing malondialdehyde (MDA), total oxidant status (TOS), 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and oxidative stress index (OSI) in homogenate supernatants obtained from liver tissue. To determine the possible hepatoprotective effect of geraniol, it was examined whether the changes in these parameters returned to normal. In addition, catalase (CAT) and total antioxidant status (TAS) analyses were performed to assess antioxidant status. MDA, catalase CAT, TAS, TOS and 8-OHdG levels were analyzed by spectrophotometric methods.
resultsParameters related to liver injury(ALT, AST, ALP, TOS, OSI, MDA and 8-OHdG) were higher, and TAS and CAT levels were lower in rats given only CE compared to the control group and the geraniol group. In this context, CE caused liver injury while also suppressing the antioxidant system. On the other hand, rats given CE + geraniol had lower liver injury-related parameters ALT, AST, ALP, TOS and OSI levels, and higher TAS and CAT levels than those given only CE. In this context, CE-induced liver injury was ameliorated with geraniol, and an increase was provided in the decreased antioxidant parameters.
conclusionGeraniol supplementation showed protective effects in ameliorating CE exposure-induced liver injury and antioxidant system suppression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.